<figure><img src="https://assets.bwbx.io/images/users/iqjWHBFdfxIU/i7TU.vso_PxI/v9/-1x-1.png"><figcaption><div><p>Source: Bloomberg, 0:00</p></div><div></div></figcaption></figure><p>Shares of Novo Nordisk were down Thursday morning after Hims &amp; Hers introduced a compounded version of its Wegovy pill. The dip came two days after Novo predicted its sales could drop as much as 13% this year as the company factors in competition from generic drugs that could crop up as its patents expire around the world. On today&#x2019;s Big Take podcast, Bloomberg reporters Naomi Kresge and Amber Tong talk to host David Gura about the year ahead for weight-loss drugs, from compounded products cutting into leading companies&#x2019; market share to generics that could upend the market globally.</p>

Shares of Novo Nordisk were down Thursday morning after Hims & Hers introduced a compounded version of its Wegovy pill. The dip came two days after Novo predicted its sales could drop as much as 13% this year as the company factors in competition from generic drugs that could crop up as its patents expire around the world.

On today’s Big Take podcast, Bloomberg reporters Naomi Kresge and Amber Tong talk to host David Gura about the year ahead for weight-loss drugs, from compounded products cutting into leading companies’ market share to generics that could upend the market globally.

Big Take: Generic Ozempic Will Change Everything

Hub Poster

Understand every aspect of the global economy – and know how to make your next move.